Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KIT V559D KIT Y823D||Advanced Solid Tumor||sensitive||Flumatinib||Preclinical||Actionable||In a preclinical study, Flumatinib treatment in transformed cells co-expressing KIT N822K and KIT V559D demonstrated decreased cell proliferation and inhibition of Kit, Erk 1/2, and Stat3 phosphorylation in culture, and led to improved survival in mouse models (PMID: 24205792).||24205792|
|KIT V559D KIT Y823D||Advanced Solid Tumor||no benefit||Sunitinib||Preclinical - Cell culture||Actionable||In a preclinical study, transformed cells co-expressing KIT Y823D and KIT V559D were insensitive to Sutent (sunitinib) in culture and in mouse models (PMID: 24205792).||24205792|
|KIT V559D KIT Y823D||Advanced Solid Tumor||no benefit||Imatinib||Preclinical||Actionable||In a preclinical study, Gleevec (imatinib) treatment in a mouse model with cells expressing KIT V559D and KIT Y823D resulted in shortened survival (PMID: 24205792).||24205792|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|